November 13-14 2017
Boston, MA

Fibrosis is not a disease; it’s a pathology.1

These words were penned insightfully back in 2012 but we are still only just coming to grips with how to effectively target fibrosis therapeutically. Conditions such as NASH, IPF, scleroderma and other forms of fibrogenesis still represent huge areas of unmet patient need.

The Anti-Fibrotic Drug Development Summit is the first meeting to assemble researchers and program leaders from cross-industry to share experiences and insights on how to better directly target the fibrotic and inflammatory drivers of these devastating diseases.

Developed in combination with experts from GSK, BMS, Pfizer and many more this forum aims to better elucidate how the underlying fibrotic biology can be more effectively drugged, to discern which models of fibrosis are the most robust and how biomarkers can be implemented into improved clinical trials designs.

Join us at this critical industry event and help shape the future treatment of fibroproliferative diseases.

1 http://www.fiercebiotech.com/r-d/industry-voices-fibrosis-stampede

“As a newcomer to the NASH space, I found the meeting to be incredibly informative and intellectually stimulating. Well organized and very comprehensive”.

NASH Summit Boston Attendee, Inception Sciences

“Best meeting for industries and valuable information. It furthers my understanding of the current situation and future perspectives”.

NASH Summit Boston Attendee, Shionogi Co & Ltd

download the brochure no logo